Academic Journals Database
Disseminating quality controlled scientific knowledge


Author(s): Gupta Sandeep | Sharma Mona | Gupta Mahesh Kumar | Nagla Kapil | Gupta Raman

Journal: International Journal of Research in Ayurveda and Pharmacy
ISSN 2229-3566

Volume: 2;
Issue: 1;
Start page: 126;
Date: 2011;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Tuberculosis | new regimens | current drug.

Today ‘Tuberculosis (TB) is acknowledged as a global health threat. As resistant strains of Mycobacterium tuberculosis have emerged slowly and due to lack and treatment failure many countries have to adapt long term and costly treatment for the patients. Due to TB 1.8 million people die every year and 5000 every day. By this data we can analyze that there is an urgent need to improve its treatment by enhancing the activity of existing agents and introducing new agents. The new regimens should have better drug tolerability profile and longer duration of action and great patient acceptability. The new agents should be more effective against MDR/XDR TB and in HIV co infected patients and active against latent TB. This review presents the drug currently used and also the advanced drug undergoing clinical trials for the treatment of tuberculosis. A short description on their mechanism of action and inhibitors acting on related biochemical targets is also provided. The focus of this review is to consider the challenges in the development of new anti TB drugs and provide an up- to-date evaluation of current therapy status and progress of the developing new agents in the phase of clinical testing as one of the strategies for the improvement of TB treatment.
RPA Switzerland

Robotic Process Automation Switzerland


Tango Rapperswil
Tango Rapperswil